<?xml version="1.0" encoding="UTF-8"?>
<p id="para490">Finally, to take account of all available results of lenalidomide as maintenance therapy for patients with multiple myeloma, we did a summary meta-analysis of our data with those previously published, including 3179 patients. These results show the HR for overall survival with the use of a lenalidomide maintenance regimen was 0·72 (95% CI 0·56–0·91; 
 <xref rid="sec1" ref-type="sec">appendix p 24</xref>).
</p>
